Myasthenia gravis inebilizumab trial (MINT): efficacy and safety in patients with generalized MG
Автор: VJNeurology
Загружено: 2025-04-15
Просмотров: 396
Описание:
Richard Nowak, MD, MS, Yale School of Medicine, New Haven, CT, discusses the results of the Phase III MINT (NCT04524273) clinical trial, which evaluated the safety and efficacy of inebilizumab in patients with generalized myasthenia gravis (MG). The trial demonstrated significant improvements in daily living in patients with acetylcholine receptor or muscle-specific kinase generalized MG. Dr Nowak highlights the unique aspects of the MINT trial, including the ability to taper down corticosteroids over time and the twice-yearly administration of inebilizumab, which offer new hope for patients with this debilitating disease. This interview took place at the 77th American Academy of Neurology (AAN) Annual Meeting in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
